A distinct impact-focused model for proactive brain health

The future of brain health

Neurogen Biomarking was founded in 2024 by neurologist and health system CEO Dr. Rani Abu Rashid, with a clear promise: to provide specialized, differentiated brain health care that is accessible to everyone, and to treat every family like our own. Headquartered in Chicago, with leadership and operations across the United States, the company serves three primary markets: US healthcare systems, employer health networks, and proactive consumers. Neurogens mission is to democratize early detection and management of brain health so that patients and their families are not set back by late diagnosis. The company’s early traction reflects real demand, a waiting list exceeding 1,000 people ahead of the official launch, and a pilot group of more than 500 participants reporting 98% satisfaction.

How it works

Neurogen is working to move early detection of Alzheimer’s disease beyond the academic laboratory and into everyday life through a differentiated, integrated service. A simple at-home blood collection measures phosphorylated tau217 (pTau217), one of the oldest approved biomarkers of Alzheimer’s pathology. This is coupled with a state-of-the-art digital cognitive assessment. Most importantly, the results are not left up to algorithms. Each participant receives a consultation with a board-certified neurologist who interprets vital signs and cognitive outcomes within the broader clinical context, including comorbidities such as kidney disease, cerebrovascular history, or cardiovascular factors. The result is clarity and a personalized plan, delivered years earlier than traditional paths typically provide.

What makes Neurogen different?

Most diagnostics provide data. Neurogen provides guidance with actionable steps. The company combines cutting-edge science, personalized neurologist care, and human-centered attention into one responsible ecosystem designed to change outcomes, not just measure them. Partnerships with leading technology providers and collaborations with digital cognitive innovators ensure accuracy and scalability. A world-class scientific advisory committee, including experts from Harvard University, Wake Forest, University of Pittsburgh, Indiana University, Amsterdam UMC, and Banner Health, works to anchor the platform to rigorous, peer-reviewed standards. Unlike offerings created primarily by business professionals, Neurogen is designed by practicing physicians and clinical trial leaders to lead responsibly within accepted medical standards. It’s not a “Test in a box.” It is a clinical path that earns confidence through determination.

Leadership and Governance

Dr. Abu Rashidfounder and CEO, has led more than 40 clinical trials focused on neurodegenerative biomarkers and previously served as the company’s chief medical officer and head of specialty services at Insight Health Systems. Join him Ken BuckPhD, Chief Strategy Officer, a veteran of healthcare projects and digital transformation, and Elisabeth ThijsenPh.D., chief scientific officer, and an internationally recognized neuroscientist in Alzheimer’s disease biomarker research. Together, they align scientific rigor with operational scale and customer experience.

Why does it matter?

Early detection changes the economic and human calculations of Alzheimer’s disease. Identifying risks early opens doors to disease-modifying therapies, targeted lifestyle interventions, clinical trials, and practical planning, opportunities that diminish dramatically once decline accelerates. Neurogen’s superior experience, rapid access, physician-led interpretation, and clear next steps turn uncertainty into agency for patients, families, employers and payers.

The way forward

Neurogen’s vision is to make proactive brain health screening as routine as cholesterol screenings. By meeting people early and guiding them through the nuances of clinical matters, the company aims to reset expectations of what compassionate modern neuroscience looks like: measurable science, delivered easily, with results at the center.

Learn more at Neurogenbiomarking.com.